Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > IMVT Immunovant > Main Composition
IMVT Immunovant
4.880
-0.250-4.87%
Post Mkt Price
4.8800.0000.00%
All
YOY
Do not show
Business

No Data

Region

No Data

Company Overview More
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
CEO: Dr. Peter Salzmann, M.B.A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...